A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

Stopped The study was terminated by sponsor for reasons of adjusted clinical development strategy.

Conditions

• Intermittent Claudication
• Peripheral Artery Disease

Interventions

• DRUG: GFH312
• OTHER: Placebo

Sponsor

Zhejiang Genfleet Therapeutics Co., Ltd.